Study # GY028

A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib In Recurrent or Metastatic Endometrioid Endometrial Cancer

Study Status:

Enrolling

Treatment Agent:

Ipatasertib, Megestrol Acetate

Description

Short Title: GY028

This phase Ib/II trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Megestrol acetate lowers the amount of estrogen and also blocks the use of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. The combination of ipatasertib and megestrol acetate may be more effective in treating endometrial cancer than megestrol acetate alone.

Resources and Links

National Clinical Trial Identified Number: NCT05538897

Information and next steps

Disease:

  • Endometrial Endometrioid Adenocarcinoma,
  • Recurrent Endometrial Endometrioid Adenocarcinoma,
  • Metastatic Endometrial Endometrioid Adenocarcinoma

Study Phase:

I/II

Physician Name:

Department:

Ask a Question